Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes

Haematologica

Volumn 97, Issue 1, 2012, Pages 56-63

  Rampazzo, Enrica ^a   Bonaldi, Laura ^b   Trentin, Livio ^a   Visco, Carlo ^c   Keppel, Sonia ^b   Giunco, Silvia ^a   Frezzato, Federica ^a   Facco, Monica ^a   Novella, Elisabetta ^c   Giaretta, Ilaria ^c   del Bianco, Paola ^b   Semenzato, Gianpietro ^a   de Rossi, Anita ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c SAN BORTOLO HOSPITAL   (Italy)

Author keywords

B Cll; Chromosomal aberrations; Telomerase; Telomere

Indexed keywords

CD38 ANTIGEN; PROTEIN KINASE ZAP 70; TELOMERASE;

ADULT; AGED; ARTICLE; B CELL LEUKEMIA; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME DELETION 11Q; CHROMOSOME DELETION 13Q; CHROMOSOME DELETION 17P; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN CELL; IGVH GENE; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; TELOMERE; TRISOMY 12;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD38; CHROMOSOME ABERRATIONS; FEMALE; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; SURVIVAL ANALYSIS; TELOMERASE; TELOMERE HOMEOSTASIS; TRANSCRIPTION, GENETIC; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 84855215427     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.049874     Document Type: Article

References (46)

1. Kipps TJ. Chronic lymphocytic leukemia. Curr Opin Hematol. 2000;7(4):223-4.
2. Friese CR, Earle C, Magazu LS, Brown JR, Neville BA, Hevelone ND, et al. Timeliness and quality of diagnostic care for Medicare recipients with chronic lymphocytic leukemia. Cancer. 2011;117(7):1470-7.
3. Plass C, Byrd JC, Raval A, Tanner SM, de la Chapelle A. Molecular profiling of chronic lymphocytic leukemia: genetics meets epi-genetics to identify predisposing genes. Br J Haematol. 2007;139(5):744-52.
4. Montserrat E., Moreno C. Genetic lesions in chronic lymphocytic leukemia: clinical implications. Curr Opin Oncol. 2009;21(6): 609-14.
5. Kienle D, Benner A, Laufle C, Winkler D, Scneider C, Buhler A, et al. Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia. Haematologica. 2010;95(1):102-9.
6. Damle RN, Wasil T, Fais F, Ghiotto F, Valletto A, Allen SL, et al. IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lympho-cytic leukemia. Blood. 1999;94(6):1840-7.
7. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated IgVH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848-54.
8. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000; 343(26): 1910-6.
9. Rossi D, Cerri M, Deambrogi C, Sozzi E, Cresta S, Rasi S, et al. The prognostic value of TP53 mutations in chronic lympho cytic leukemia is independent of del17p13: implications for overall survival and chemo refractoriness. Clin Cancer Res. 2009;15(3): 995-1004.
10. Zenz T, Mertens D, Dohner H, Stilgenbauer S. Importance of genetics in chronic lymphocytic leukemia. Blood Rev. 2011;25(3):131-7.
11. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature. 1990;345(6274):458-60.
12. Blackburn EH, Greider CW, Szostak JW. Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nat Med. 2006;12(10): 1133-8.
13. Hackett JA, Greider CW. Balancing instability: dual roles for telomerase and telomere dysfunction in tumorigenesis. Oncogene. 2002;21(4):619- 626.
14. Meeker AK, Hicks JL, Iacobuzio-Donahue CA, Montgomery EA, Westra WH, Chan TY, et al. Telomere length abnormalities occur early in the initiation of epithelial carcinogen-esis. Clin Cancer Res. 2004;10(10): 3317-26.
15. Calado RT, Young NS. Telomere diseases. N Engl J Med. 2009;361(24):2353-65.
16. Ricca I, Rocci A, Drandi D, Francese R, Compagno M, Lobetti Bodoni C, et al. Telomere length identifies two different prognostic subgroups among VH-unmutat-ed B-cell chronic lymphocytic leukemia patients. Leukemia. 2007;21(10):697-705.
17. Roos G, Kröber A, Grabowski P, Kienle D, Buhler A, Dohner H, et al. Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia. Blood. 2008;111(12):2246-52.
18. Lin TT, Letsolo BT, Jones RE, Rowson J, Pratt J, Hewamana S, et al. Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis. Blood. 2010;116(11): 1899-907.
19. Morin GB. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell. 1989;59(3):521-9.
20. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science. 1997;277(5328):955-9.
21. Poole JC, Andrews LG, Tollefsbol TO. Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene. 2001;269(1-2):1-12.
22. Stewart SA, Weinberg RA. Telomerase and human tumorigenesis. Semin Cancer Biol. 2000;10(6):399-406.
23. Ohyashiki JH, Sashida G, Tauchi T, Ohyashiki K. Telomeres and telomerase in hematologic neoplasia. Oncogene. 2002; 21(4):680-7.
24. Briatore F, Barrera G, Pizzimenti S, Toaldo C, Casa CD, Laurora S, et al. Increase of telomerase activity and hTERT expression in myelodysplastic syndromes. Cancer Biol Ther. 2009;8(10):883-9.
25. Deville L, Hillion J, Ségal-Bendirdjian E. Telomerase regulation in hematological cancers: a matter of stemness? Biochim Biophys Acta. 2009;1792(4):229-39.
26. Trentin L, Ballon G, Ometto L, Perin A, Basso U, Chieco-Bianchi L, et al. Telomerase activity in chronic lymphopro-liferative disorders of B cell lineage. Br J Haematol. 1999;106(3):662-8.
27. Tchirkov A, Chaleteix C, Magnac C, Vasconcelos Y, David F, Michel A, et al. hTERT expression and prognosis in B-chronic lymphocytic leukemia. Ann Oncol. 2004;15(10):1476-80.
28. Terrin L, Trentin L, Degan M, Corradini I, Bertorelle R, Carli P, et al. Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same IgVH mutation status and different outcome. Leukemia. 2007;21(5):965-72.
29. Damle RN, Batliwalla FM, Ghiotto F, Valetto A, Albesiano E, Sison C, et al. Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations. Blood. 2004;103(2):375-82.
30. Hallek M, Cheson BD, Catovsky D, Calligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Work on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 111(12):5446-56.
31. Rampazzo E, Bertorelle R, Serra L, Terrin L, Candiotto C, Pucciarelli S, et al. Relationship between telomere shortening, genetic instability, and site of tumour origin in colorectal cancers. Br J Cancer. 2010; 102(8):1300-5.
32. Hou M, Xu D, Björkholm M, Gruber A. Real-time quantitative telomeric repeat amplification protocol assay for the detection of telomerase activity. Clin Chem. 2001;47(3):519-24.
33. Grabowski P, Hultdin M, Karlsson K, Tobin G, Aleskog A, Thunberg U, et al. Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status. Blood. 2005;105(12):4807-12.
34. Dolcetti R, De Rossi A. Telomere/telom-erase interplay in virus-driven and virus-independent lymphomagenesis:patho-genetic and clinical implications. Med Res Rev. 2010, DOI 10.1002/ med.20211
35. Weng NP, Granger L, Hodes RJ. Telomere lengthening and telomerase activation during human B cell differentiation. Proc Natl Acad Sci USA. 1997;94(20):10827-32.
36. Norrback KF, Dahlenborg K, Carlsson R, Roos G. Telomerase activation in normal B lymphocytes and non-Hodgkin's lym-phomas. Blood. 1996;88(1):222-9.
37. Rossi D, Lobetti Bodoni C, Genuardi E, Monitillo L, Drandi D, Cerri M, et al. Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia. Leukemia. 2009;23(6):1062-72.
38. Artandi SE, DePinho RA. Telomeres and telomerase in cancer. Carcinogenesis. 2010;31(1):9-18.
39. Hiyama E, Hiyama K. Telomere and telom-erase in stem cells. Br J Cancer. 2007;96(7): 1020-4.
40. Poncet D, Belleville A, Kint de Roodenbeke C, Roborel de Climens A, Ben Simon E, Merle-Beral H, et al. Changes in the expression of telomere maintenance genes suggest global telomere dysfunction in B-chronic lymphocytic leukemia. Blood. 2008;111(4):2388-91.
41. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lym-phocytic leukemia. Proc Natl Acad Sci USA. 2002;99(24):15524-9.
42. Ouillette P, Erba H, Kujawski L, Kaminski M, Shedden K, Malek SN. Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14. Cancer Res. 2008;68(4):1012-21.
43. Cao Y, Li H, Deb S, Liu JP. TERT regulates cell survival independent of telomerase enzymatic activity. Oncogene. 2002;21 (20):3130-8.
44. Massard C, Zermati Y, Pauleau AL, Larochette N, Metivier D, Sabatier L, et al. hTERT: a novel endogenous inhibitor of the mitochondrial cell death pathway. Oncogene. 2006;25(33):4505-14.
45. Jin X, Beck S, Sohn YW, Kim JK, Kim SH, Yin J, et al. Human telomerase catalytic subunit (hTERT) suppresses p53-mediated anti-apoptotic response via induction of basic fibroblast growth factor. Exp Mol Med. 2010;42(8):574-82.
46. Gonzales D, Martinez P, Wade R, Hockley S, Oscier D, Matutes E, et al. Mutational status of the TP53 gene as a predictor of response and survival patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol. 2011;29(16):2223-9.